Business
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480
About this update from Coherus Oncology, Inc.
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. “We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “We are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts.” “We are aggressively advancing casdozokitug, our first-in-class IL-27 targeting antibody in 1L hepatocellular carcinoma, which demonstrated a 17% complete response rate in a previous Phase 2 study,” said Rosh Dias, MD, Chief Medical Officer. “At the same time, we also have a broad clinical program with tagmokitug, our highly selective CCR8 targeting cytolytic antibody, in multiple tumor cohorts including gastrointestinal cancers and head and neck cancer with strong scientific and clinical rationale in each. We now look forward to initiating the combination study with J&J’s T-cell engager pasritamig, in metastatic castration resistant prostate cancer (mCRPC), in the second half of this year.” “Tumor targeted T regulatory cell depleting agents have broad potential applicability in combination with immune agents like TCE and toripalimab, ADCs, T-cell engagers and radiotherapy,” said Theresa LaVallee, PhD, Coherus Chief Scientific and Development Officer. “With a potentially best-in-class molecule we look forward to advancing tagmokitug combinations both with partners and with LOQTORZI.” RECENT BUSINESS HIGHLIGHTS LOQTORZI® (toripalimab-tpzi) Commercial Updates LOQTORZI net re...
View stock analysis, news, and events for Coherus Oncology, Inc.